Arslan Fatih, Gökgöz Mert Cemal, Binar Murat, Aydemir Emre, Durmaz Abdullah
Department of Otolaryngology-Head and Neck Surgery, Beytepe Murat Erdi Eker State Hospital, Ankara, Turkey.
Ear Nose Throat J. 2018 Apr-May;97(4-5):E1-E4.
We conducted a prospective study to investigate the effectiveness of pharmacologic treatment on alleviating facial paralysis, as well as the anxiety and depression that are associated with it. Our study population was made up of 105 patients-59 men and 46 women, aged 18 to 60 years (mean: 38.2)-who had acute idiopathic peripheral facial paralysis. Before treatment, paralysis was classified as House-Brackmann grade II or III in 44 patients (41.9%) and grade IV to VI in the remaining 61 (58.1%). After treatment, 73 patients (69.5%) improved to grade I, 29 (27.6%) were at grade II or III, and only 3 (2.9%) remained at grade IV or higher. Mean scores on the Beck anxiety inventory, the Beck depression inventory, and the Beck hopelessness scale were 20.30, 19.75, and 7.57, respectively, before treatment and 5.72, 5.68, and 2.85 afterward; the difference in all three measures was statistically significant (p < 0.001). We found no correlation between the degree of facial paralysis and anxiety levels (r = 0.094, p = 0.338) or depression levels (r = 0.181, p = 0.064). Clinicians should consider asking patients with peripheral facial paralysis about their feelings of anxiety, depression, and hopelessness and refer them for a psychiatric consultation if necessary.
我们进行了一项前瞻性研究，以调查药物治疗在缓解面瘫以及与之相关的焦虑和抑郁方面的有效性。我们的研究对象包括105例年龄在18至60岁（平均38.2岁）之间的急性特发性周围性面瘫患者，其中男性59例，女性46例。治疗前，44例患者（41.9%）的面瘫被分类为House-Brackmann II级或III级，其余61例（58.1%）为IV级至VI级。治疗后，73例患者（69.5%）改善至I级，29例（27.6%）为II级或III级，只有3例（2.9%）仍为IV级或更高等级。治疗前，贝克焦虑量表、贝克抑郁量表和贝克绝望量表的平均得分分别为20.30、19.75和7.57，治疗后分别为5.72、5.68和2.85；所有三项指标的差异均具有统计学意义（p < 0.001）。我们发现面瘫程度与焦虑水平（r = 0.094，p = 0.338）或抑郁水平（r = 0.181，p = 0.064）之间无相关性。临床医生应考虑询问周围性面瘫患者的焦虑、抑郁和绝望感受，必要时将他们转介进行精神科咨询。
